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was not protective of end-stage renal failure. We studied
another 75 patients who entered a randomized controlled
trial (37 were on treatment and 38 controls) from 1999 to
2000 and were followed up for 5 years. Leaving out patients
on combined therapy, we again found that patients on ACEI
alone had a significantly higher incidence of progression to
end-stage renal failure when compared to those on ATRA
alone (Table 1b).
It is our belief that ATRA is superior to ACEI. Apart from
its ability to reduce or block the effects of ACE, ATRA by
itself has other renoprotective abilities like reducing trans-
forming growth factor-b production in the glomerulus,
which causes mesangial cell proliferation and contraction. In
diabetic nephropathy and IgA nephropathy, mesangial cell
injury is one of the main events in glomerular injury leading
to glomerular sclerosis.3 It would be interesting for Suissa
and co-workers to examine their data regarding the role of
ATRA in preventing end-stage renal failure.
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To the Editor: Suissa et al.1 reported on the risk of renal
failure in diabetics treated with angiotensin-converting
enzyme (ACE) inhibitors. They used a nested case–control
design and thus excluded over 1800 patients from the final
analysis. It is not clear why the entire cohort could not have
been analyzed to address the issue of mortality. ACE
inhibitors are intentionally prescribed to reduce mortality2
and to prolong time to dialysis.3 It would be informative for
the readers if the authors presented data for these two
outcomes both separately and combined (e.g. death, dialysis,
or transplant) for those prescribed ACE inhibitors and those
not, using the entire cohort of 6102 patients. Only with this
information can the readers determine if their conclusions
are valid. As the authors themselves state ‘ACE inhibitors
prolong life, thus increasing the opportunity for end-stage
renal disease incidence’.1 In addition, a stepped-care
approach to hypertension was often used in the era of this
study.4 As such, ACE inhibitors may have been prescribed to
patients with difficult to control blood pressure. It would be
useful to know if the database had any blood pressure values
and if there were any differences between the groups, as the
severity of hypertension is arguably the single most
important factor for progression of diabetic nephropathy.
In view of the above comments, the conclusion that ACE
inhibitors may increase the risk of renal failure in diabetes
may not be justified.
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To the Editor: Recently, Suissa et al.1 reported that use of
ACE inhibitors (ACEi) by hypertensive diabetic patients is
not associated with a long-term decreased risk of end-stage
renal disease. They suggest that ACEi while providing an early
benefit to the kidney could in fact damage the kidney in the
longer term by mechanisms still unknown.
Experimental data from our group support the possibility
of such adverse effects of renin–angiotensin system blockade
Table 1 | (a) Anti-proteinuric response to ACEI/ATRA therapy




Responders (n=9) 2 7
Non-responders (n=7) 6 1
Pearson’s w2 6.3 (Po0.02)
(b)
Normal renal function 1 16
ESRF 5 7
Pearson’s w2 5.5 (Po0.02)
ACEI, angiotensin-converting enzyme inhibitor; ATRA, angiotensin II receptor
antagonist; ESRF, end-stage renal failure.
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on the kidney. In proteinuric rats, the combination of ACEi
and a low sodium diet elicits pronounced renal interstitial
damage, despite a significant reduction of proteinuria.2 As
similar effects were found in healthy rats, the renal damage
was not owing to particularities of the model, but related to
the ACEi regimen. This is in line with earlier data in
experimental renal transplantation, with monotherapy
ACEi.3 These data are distressing, as the ACEi regimens
induced renal fibrosis in spite of a reduction in proteinuria
and blood pressure, that is, an improvement of the
established clinical criteria for a good response to therapy.
In human, it is usually not feasible to monitor renal
structural damage during therapy. Accordingly, considering
the dissociation between renal fibrosis and the intermediate
parameters blood pressure and proteinuria, therapy-asso-
ciated progressive renal damage during renin–angiotensin
system blockade in human cannot easily be recognized, and
would require large, hard end point studies to become
manifest. Although the mechanism underlying the ACEi-
induced renal fibrosis deserves further study, our data
provide a possible explanation for the increased risk of
end-stage renal disease found by Suissa et al.1
The incidence of end-stage renal disease is increasing
worldwide, despite extensive use of renin–angiotensin system
blockers. It would be prudent not to take their long-term
renoprotective effect for granted, scrutinize their effects on
renal structural damage in experimental studies, and critically
evaluate their outcome in human during long-term follow-up.
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We thank the authors for their interest in our paper. Woo
et al.1 suggest that our findings apply only to angiotensin-
converting enzyme (ACE) inhibitors and not to angioten-
sin receptor antagonists (angiotensin II receptor blockers
or all-trans retinoic acids). The data they provide on 16
patients suggest that all-trans retinoic acid patients have a
higher rate of antiproteinuric response than patients on
ACE inhibitors (rate ratio 3.5; 95% confidence interval:
1.0–11.9). They also provide data on 29 patients followed
for 5 years, suggesting that patients on ACE inhibitors are
at higher risk of end-stage renal failure than patients on
all-trans-retinoic acids (relative risk 2.7; 95% confidence
interval: 1.3–5.6). These data, although based on small
samples, advocate the need for further large long-term
comparative studies to shed more light on this question.
Hiremath et al. imply that the 1800 patients not
included in the analysis would have been useful. This is
not so since, to reduce the impact of confounding bias, we
matched our renal failure cases to all available patients in
the cohort of the same age, type and duration of diabetes.
The 1800 ‘excluded’ patients were of different age, type and
duration of diabetes than the cases, thus uninformative
with respect to the question of renal failure and hence not
relevant to the analysis. We agree that it would be of
interest to assess the effect of ACE inhibitors on all-cause
mortality in this cohort, an analysis that we will consider
and report on subsequently. We did not have blood
pressure levels available to control for confounding by
severity, but did attempt to control for related conditions
also associated with renal failure. In any case, despite the
careful attention to control of confounding, it is important
to reiterate that possibility of uncontrolled confounding
cannot be ruled out with such observational studies.
Our findings, as well as the observations presented by
Woo et al., must be placed in their proper context of an
observational study and are more hypothesis generating
than conclusive. Ideally, long-term randomized controlled
trials comparing ACE inhibitors to angiotensin II receptor
blocker/all-trans retinoic acids will be required to clarify
these questions.
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Late-onset renal failure from
RAAS blockade
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To the Editor: We read with special interest and excitement,
the recent publication by Suissa et al.1 They demonstrated an
increased rate ratio of end-stage renal disease of 4.2 (95%
confidence interval: 2.0–9.0), among diabetic patients, after
3 years of angiotensin-converting enzyme inhibition.
This represents a validation of our recent report of a
previously unrecognized syndrome of late-onset renal failure
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